Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.29
-$0.11(-1.36%)
At close: 4:00 PM EST
$7.29
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.73 - $9.54
Previous CloseN/A
Volume82.15K
Average Volume (3M)546.64K
Market Cap
$800.60M
Enterprise Value$337.30M
Total Cash (Recent Filing)$114.73M
Total Debt (Recent Filing)$16.99M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding103,436,420
10 Day Avg. Volume656,891
30 Day Avg. Volume546,640
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-587.63
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$20.67Price Target Upside183.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Phase 3 Program Nearing EnrollmentA near-complete, registration‑enabling Phase 3 trial creates a clear long-term inflection point: positive topline results could enable regulatory filing and commercialization paths, materially de‑risking the business versus earlier-stage assets and concentrating value in a definable milestone.
Substantial Equity Raise Extends RunwayA large, oversubscribed financing materially strengthens liquidity and funds pivotal clinical and registration activities. This reduces near‑term fundraising pressure, supports sustained R&D execution through key milestones, and allows management to focus on development rather than immediate capital raises.
Modest Financial LeverageLow debt relative to equity gives the company financial flexibility typical of R&D biotechs: it lowers solvency risk and interest burdens, enabling continued investment in trials without large fixed financing costs and preserving optionality during development cycles.
Bears Say
Pre-revenue With Widening Net LossesBeing pre‑commercial with growing net losses means the company must rely on external capital until product sales begin. Continued negative earnings over time amplify funding needs and create execution risk if clinical setbacks delay potential revenue generation.
Persistent And Accelerating Cash BurnRising operating cash outflows indicate structural spending growth to support multiple trials. High, sustained burn depletes liquidity and increases the likelihood of future financings, which can dilute shareholders and distract management from clinical execution.
Material Equity Erosion And Dilution HistorySignificant decline in equity over recent years signals repeated dilutive financings and capital consumption. This trend reduces per‑share economic ownership, can compress future capital options, and underscores dependence on markets to fund R&D until commercialization.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.73 and its highest was $9.54 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $800.60M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.398 by -$0.102.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.38.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 103,436,420 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.398. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (183.49% Upside)
$20.67 (183.49% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.50%
12-Months-Change
Fundamentals
Return on Equity
-78.12%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
AURA Stock 12 Month Forecast
Average Price Target
$20.67
▲(183.49% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.17% Insiders
5.18% Mutual Funds
33.37% Other Institutional Investors
50.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---